Blog

Science

Amil Druzic: The significant efficacy of FOLFIRINOX in metastatic pancreatic cancer in a real-world setting

Amil Druzic/LinkedIn

Jan 1, 2025, 06:18

Amil Druzic: The significant efficacy of FOLFIRINOX in metastatic pancreatic cancer in a real-world setting

Amil Druzic, Oncology and Radiotherapy Resident at Clinical center University of Sarajevo, shared a post on LinkedIn:

“Our new study, published in Sarajevo Medical Journal demonstrates the significant efficacy of FOLFIRINOX in treating metastatic pancreatic cancer in a real-world setting. Personalized approaches, including genetic profiling, microbiome analysis, and AI integration, offer promising avenues to enhance treatment outcomes and improve quality of life for patients.”

Enhanced Survival Outcomes with FOLFIRINOX in Initial Metastatic Pancreatic Cancer: Single-Center

Authors: Emir Sokolovic et al.

Amil Druzic

Amil Družić Amina Aljic Anes Pasic Berisa Hasanbegovic cancer Elma Kapisazovic Emina Borovac-Gurda Emir Sokolović Jasmina Redzepagic Mattar Layan OncoDaily Oncology Sejla Ceric Semir Beslija Una Stojanovic

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care